Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study

Antoine Kimmoun, Kevin Duarte, Veli Pekka Harjola, Tuukka Tarvasmäki, Bruno Levy, Alexandre Mebazaa, Sebastien Gibot*, Katerina Koniari, Astrinos Voumvourakis, Apostolos Karavidas, John Parissis, Jordi Sans-Rosello, Montserrat Vila, Albert Duran-Cambra, Alessandro Sionis, Jiri Parenica, Roman Stipal, Ondrej Ludka, Marie Palsuva, Eva GanovskaPetr Kubena, Jindrich Spinar, Matias G. Lindholm, Christian Hassager, Lars Køber, Tom Bäcklund, Johan Lassus, Raija Jurkko, Heli Tolppanen, Markku S. Nieminen, Kristiina Järvinen, Tuomo Nieminen, Kari Pulkki, Leena Soininen, Reijo Sund, Ilkka Tierala, Jukka Tolonen, Marjut Varpula, Tuomas Korva, Mervi Pietilä, Anne Pitkälä, Rossella Marino, Salvatore Di Somma, Marco Metra, Michela Bulgari, Valentina Lazzarini, Valentina Carubelli, Alexandra Sousa, Jose Silva-Cardoso, Carla Sousa, CardShock Investigators and the GREAT network

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

5 Citationer (Scopus)
7 Downloads (Pure)

Abstract

Aims: Optimal outcome after cardiogenic shock (CS) depends on a coordinated healing response in which both debris removal and extracellular matrix tissue repair play a crucial role. Excessive inflammation can perpetuate a vicious circle, positioning leucocytes as central protagonists and potential therapeutic targets. High levels of circulating Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), were associated with death in acute myocardial infarction confirming excessive inflammation as determinant of bad outcome. The present study aims to describe the association of soluble TREM-1 with 90-day mortality and with various organ injuries in patients with CS. Methods and results: This is a post-hoc study of CardShock, a prospective, multicenter study assessing the clinical presentation and management in patients with CS. At the time of this study, 87 patients had available plasma samples at either baseline, and/or 48 h and/or 96–120 h for soluble TREM-1 (sTREM-1) measurements. Plasma concentration of sTREM-1 was higher in 90-day non-survivors than survivors at baseline [median: 1392 IQR: (724–2128) vs. 621 (525–1233) pg/mL, p = 0.008), 48 h (p = 0.019) and 96–120 h (p = 0.029). The highest tertile of sTREM-1 at baseline (threshold: 1347 pg/mL) was associated with 90-day mortality with an unadjusted HR 3.08 CI 95% (1.48–6.42). sTREM-1 at baseline was not associated to hemodynamic parameters (heart rate, blood pressure, use of vasopressors or inotropes) but rather with organ injury markers: renal (estimated glomerular filtration rate, p = 0.0002), endothelial (bio-adrenomedullin, p = 0.018), myocardial (Suppression of Tumourigenicity 2, p = 0.002) or hepatic (bilirubin, p = 0.008). Conclusion: In CS patients TREM-1 pathway is highly activated and gives an early prediction of vital organ injuries and outcome. Graphic abstract: [Figure not available: see fulltext.].

OriginalsprogEngelsk
TidsskriftClinical Research in Cardiology
Vol/bind111
Udgave nummer6
Sider (fra-til)604-613
ISSN1861-0684
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CardShock study was supported by grants from Aarne Koskelo Foundation, the Finnish Cardiac Foundation, and the Finnish State funding for university-level health research.

Publisher Copyright:
© 2021, Springer-Verlag GmbH, DE part of Springer Nature.

Citationsformater